🚨 The October issue of Practical Dermatology is now online! - Explore The Evolving Landscape of Atopic Dermatitis, featuring expert perspectives on treatment options, patient-reported outcomes, and emerging considerations in care➡️ ow.ly/tVgA50ZZuPQ #PracticalDermatology #AtopicDermatitis #Dermatology #SkinHealth #DermatologyResearch

🎙️👨‍⚕️NEW DISEASE DEEP DIVE: Walter Liszewski, MD, and Naiem Issa, MD, discuss how to diagnose chronic spontaneous urticaria, avoid unnecessary testing, and apply updated treatment recommendations, including newer systemic therapies.✨💉 🎧 Listen here ➡️ ow.ly/xH4O50ZYNyx

📊👀NEW DATA: The investigational IL-23p19 inhibitor ORKA-001 produced high rates of complete skin clearance through week 28 in adults with moderate-to-severe plaque psoriasis who received their last dose at week 4, according to results from the phase 2a EVERLAST-A trial presented in a research poster at the 2026 Fall Clinical Dermatology Conference ➡️ ow.ly/wfkU50ZYJz5

👨‍⚕️👩‍⚕️👨‍⚕️👩‍⚕️📊PANEL PROPOSES MOLLUSCUM TREATMENT ALGORITHM: A pediatric dermatology expert panel has proposed a practical treatment algorithm for molluscum contagiosum that emphasizes disease severity, family preferences, and shared decision-making ➡️ ow.ly/5jBq50ZYxS7

NEW ACQUISITION: Galderma to Acquire ZO Skin Health for $1.5 Billion: Galderma announced an agreement to acquire ZO Skin Health for $1.5 billion, a move it says will expand its dermatological skincare business and strengthen its presence in the physician-dispensed skincare market. Read more ➡️ ow.ly/UZfy50ZXS8W

📊🩺 NEW DATA: Researchers have announced new phase 1b data for SYX-5219, an investigational oral PKM2 modulator, which showed improvements in atopic dermatitis severity and itch over 6 weeks ➡️ ow.ly/bsJV50ZXjwb #SkinHealth #PKM2Modulator #MedicalResearch #ClinicalTrials #Dermatology #AtopicDermatitis #ClinicalResearch

📊 🔍 ICYMI: Dr. Shawn Kwatra analyzes new data from the phase 3b ADtouch study for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas ➡️ ow.ly/NYCN50ZWQFw #AtopicDermatitis #SkinHealth #SkinDisease #ClinicalResearch

👀 📊GAPS IN ATOPIC DERM SKIN MODELS: A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD) ➡️ ow.ly/g8Bw50ZWysc #SkinResearch #Dermatology #SkinHealth #AtopicDermatitis

🎤👨‍⚕️📊NEW: Study investigator Dr. Shawn Kwatra talked with Practical Dermatology about new Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) and how it may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas 👉 ow.ly/u3XV50ZVtve

🚨🆕 The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines 🔬👉ow.ly/BBbn50ZVxgU

🏆 NEWS: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) ZORYVE® (roflumilast) HCP cream 0.15% has received Marie Claire’s inaugural Best Prescription Skin Solution Award ➡️ ow.ly/zrCS50ZV8cU #Dermatology #AtopicDermatitis #Eczema #ZORYVE #Dermatology

🌿 EARLY ENVIRONMENTAL FACTORS FOR AD: Environmental factors may play an important role in pediatric atopic dermatitis, according to new research ➡️ ow.ly/I29g50ZUtRR #AtopicDermatitis #PediatricDermatology #Dermatology #Eczema

📊👨‍⚕️🎤ICOTROKINRA UPDATE: New two-year phase 3 ICONIC-TOTAL data presented at EADV 2026 showed sustained responses with oral icotrokinra among adults and adolescents with plaque psoriasis involving high-impact sites. Read more ➡️ ow.ly/i85P50ZUkbA #Icotrokinra #PlaquePsoriasis #EADV2026 #SkinHealth

🩺👉 SKIN MINUTE: Linda Stein Gold, MD, discusses a new pooled post hoc analysis evaluating the efficacy and safety of #tapinarof cream 1% in the treatment of atopic dermatitis ➡️ ow.ly/YAFZ50ZUeXT #Tapinarof #DermatologyResearch #AtopicDermatitis #SkinHealth

📊🎤👨‍⚕️LITIFILIMAB MEETS PRIMARY ENDPOINT: Phase 2 Part A of the AMETHYST study met its primary endpoint, with more patients receiving litifilimab achieving clear or almost clear skin by CLA-IGA-R erythema score at week 16 than those receiving placebo ➡️ ow.ly/Qf4n50ZU74z #Dermatology #Lupus #ClinicalTrials #SkinHealth #MedTwitter #Aesthetics

🔬 NEW DAX DATA: Evaluated doses of daxdilimab significantly improved CLASI-A scores versus placebo at week 24, according to new data presented at 2026 EADV Congress in Vienna ➡️ ow.ly/E3OG50ZTmAK #Dermatology #DiscoidLupus #CutaneousLupus #ClinicalTrials

💊🧴SKIN TO BELIEVE IN: Simone Biles is sharing her experience with seborrheic dermatitis and eczema as part of Arcutis Biotherapeutics’ new Skin to Believe In campaign ➡️ ow.ly/qcMG50ZSTt9 #Dermatology #SeborrheicDermatitis #AtopicDermatitis #Eczema #SkinHealth #DermatologyNews

💉🤰NEW: Biologic therapy was not associated with increased adverse pregnancy outcomes among patients with psoriasis in a large real-world cohort study published in the Journal of the American Academy of Dermatology 👉 ow.ly/6Zig50ZSp8p #PsoriasisCare #PatientSafety #DermatologyResearch #BiologicTherapy #MedicalResearch

🩺👨‍⚕️👩‍⚕️MANAGING DIFFICULT TREATMENT COMBOS FOR PSO: During a case-based session at the Science of Skin Summit, Scott Drew, DO; April Armstrong, MD, MPH; and Erin Boh, MD, PhD, explored how complex psoriasis presentations can require clinicians to move beyond standardized treatment algorithms and individualize management ➡️ ow.ly/ZWem50ZREng #PsoriasisCare #SkinHealth #SkinSummit #ClinicalDermatology

FDA Approves First Treatment for Ataxia-Telangiectasia: The US Food and Drug Administration (FDA) has approved Aqneursa (levacetylleucine; IntraBio) for the treatment of adults and pediatric patients with ataxia-telangiectasia (A-T) who weigh at least 15 kg, providing the first FDA-approved treatment for the rare multisystem disorder. Read more ➡️ ow.ly/6bls50ZRaB0 #AtaxiaTelangiectasia #RareDisease #RareDisorders #FDAApproval #Dermatology